Zobrazeno 1 - 10
of 525
pro vyhledávání: '"Alberto J, Espay"'
Autor:
Alberto J. Espay, Jose Biller
With easy-to-read, high-yield coverage of essential information in neurology, Concise Neurology: A Focused Review is a practical, everyday reference for busy practitioners, fellows, residents, and students who need a rapid overview of a complex subje
Autor:
David L. Perez, Timothy R. Nicholson, Ali A. Asadi-Pooya, Matthew Butler, Alan J. Carson, Anthony S. David, Quinton Deeley, Ibai Diez, Mark J. Edwards, Alberto J. Espay, Jeannette M. Gelauff, Johannes Jungilligens, Mark Hallett, Richard A.A. Kanaan, Marina A.J. Tijssen, Kasia Kozlowska, W. Curt LaFrance, Jr, Ramesh S. Marapin, Carine W. Maurer, Antje A.T.S. Reinders, Petr Sojka, Jeffrey P. Staab, Jon Stone, Jerzy P. Szaflarski, Selma Aybek
Publikováno v:
NeuroImage: Clinical, Vol 41, Iss , Pp 103573- (2024)
Externí odkaz:
https://doaj.org/article/09c26796cadb46a59a8a282813b94ac5
Autor:
Silvia Rota, Daniele Urso, Daniel J. van Wamelen, Valentina Leta, Iro Boura, Per Odin, Alberto J. Espay, Peter Jenner, K. Ray Chaudhuri
Publikováno v:
Translational Neurodegeneration, Vol 11, Iss 1, Pp 1-14 (2022)
Abstract Continuous drug delivery (CDD) is used in moderately advanced and late-stage Parkinson’s disease (PD) to control motor and non-motor fluctuations (‘OFF’ periods). Transdermal rotigotine is indicated for early fluctuations, while subcut
Externí odkaz:
https://doaj.org/article/26cf9af741ac4f178127aa79fb31f5c4
Autor:
Andrea Sturchio, Emily M. Rocha, Marcelo A. Kauffman, Luca Marsili, Abhimanyu Mahajan, Ameya A. Saraf, Joaquin A. Vizcarra, Ziyuan Guo, Alberto J. Espay
Publikováno v:
Brain Sciences, Vol 14, Iss 2, p 151 (2024)
Animal models have been used to gain pathophysiologic insights into Parkinson’s disease (PD) and aid in the translational efforts of interventions with therapeutic potential in human clinical trials. However, no disease-modifying therapy for PD has
Externí odkaz:
https://doaj.org/article/f172463d7e0e4ec7abae20cf0d6114dd
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundPimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease (PD) psychosis.AimWe aimed to evaluate m
Externí odkaz:
https://doaj.org/article/895728bd476845e8ab214aa5f5e0e4af
Autor:
Luca Marsili, Samuel Marcucci, Joseph LaPorta, Martina Chirra, Alberto J. Espay, Carlo Colosimo
Publikováno v:
Biomedicines, Vol 11, Iss 5, p 1406 (2023)
Paraneoplastic neurological syndromes (PNS) include any symptomatic and non-metastatic neurological manifestations associated with a neoplasm. PNS associated with antibodies against intracellular antigens, known as “high-risk” antibodies, show fr
Externí odkaz:
https://doaj.org/article/0972279a1b3c4a2c8234a99c2ebe1c86
Autor:
Caroline M. Tanner, Steven R. Cummings, Michael A. Schwarzschild, Ethan G. Brown, E. Ray Dorsey, Alberto J. Espay, Nicholas B. Galifianakis, Samuel M. Goldman, Irene Litvan, Nijee Luthra, Nikolaus R. McFarland, Kyle T. Mitchell, David G. Standaert, Douglas C. Bauer, Susan L. Greenspan, James C. Beck, Kenneth W. Lyles
Publikováno v:
npj Parkinson's Disease, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract The Trial of Parkinson’s And Zoledronic acid (TOPAZ, https://clinicaltrials.gov/ct2/show/NCT03924414 ) is a unique collaboration between experts in movement disorders and osteoporosis to test the efficacy of zoledronic acid, an FDA-approve
Externí odkaz:
https://doaj.org/article/de1c2ed76f6f4436af9d6293955c5287
Autor:
Ruth B. Schneider, Larsson Omberg, Eric A. Macklin, Margaret Daeschler, Lauren Bataille, Shalini Anthwal, Taylor L. Myers, Elizabeth Baloga, Sidney Duquette, Phil Snyder, Katherine Amodeo, Christopher G Tarolli, Jamie L. Adams, Katherine F Callahan, Joshua Gottesman, Catherine M. Kopil, Codrin Lungu, Alberto Ascherio, James C. Beck, Kevin Biglan, Alberto J. Espay, Caroline Tanner, David Oakes, Ira Shoulson, Dan Novak, Elise Kayson, Earl Ray Dorsey, Lara Mangravite, Michael A. Schwarzschild, Tanya Simuni, the Parkinson Study Group AT‐HOME PD Investigators
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 2, Pp 308-320 (2021)
Abstract Objective The expanding power and accessibility of personal technology provide an opportunity to reduce burdens and costs of traditional clinical site‐centric therapeutic trials in Parkinson’s disease and generate novel insights. The val
Externí odkaz:
https://doaj.org/article/7feb687f3d094d1c9e817ead9428641d
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
Long-read sequencing (LRS) technologies have been recently introduced to overcome intrinsic limitations of widely-used next-generation sequencing (NGS) technologies, namely the sequencing limited to short-read fragments (150–300 base pairs). Since
Externí odkaz:
https://doaj.org/article/396cac122b5446c9af9b2b91146ecb14
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Autor:
Daniel Weintraub, Chelsea Caspell‐Garcia, Tanya Simuni, Hyunkeun R. Cho, Christopher S. Coffey, Dag Aarsland, Roy N. Alcalay, Matthew J. Barrett, Lana M. Chahine, Jamie Eberling, Alberto J. Espay, Jamie Hamilton, Keith A. Hawkins, James Leverenz, Irene Litvan, Irene Richard, Liana S. Rosenthal, Andrew Siderowf, Michele York, Parkinson’s Progression Markers Initiative
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 7, Iss 4, Pp 449-461 (2020)
Abstract Objective To determine the evolution of numerous neuropsychiatric symptoms and cognitive abilities in Parkinson disease from disease onset. Methods Prospectively collected, longitudinal (untreated, disease onset to year 5), observational dat
Externí odkaz:
https://doaj.org/article/1733fdc8d0954e2d9d18b60b48a839a0